公开(公告)号：US10420763B2

公开(公告)日：2019-09-24

申请号：US16005105

申请日：2018-06-11

Applicant: Sunovion Pharmaceuticals Inc.

Inventor： Anthony John Giovinazzo ,  David Bruce Hedden ,  Marc L. De Somer ,  Nathan John Bryson

IPC: A61K9/70 ,  A61F13/00 ,  A61K31/485 ,  A61K9/00 ,  A61K9/06 ,  A61K9/20 ,  A61K31/473 ,  A61K47/02 ,  A61K47/10 ,  A61K47/18 ,  A61P25/16 ,  A61P15/10

Abstract: Disclosed are sublingual formulations of apomorphine, and methods of treating Parkinson's disease therewith. The sublingual formulations are films or strips having a first portion comprising apomorphine particles comprising an acid addition salt of apomorphine and a second portion comprising a pH neutralizing agent.

公开(公告)号：US10336732B2

公开(公告)日：2019-07-02

申请号：US15819372

申请日：2017-11-21

Applicant: Sunovion Pharmaceuticals Inc. ,  PGI Drug Discovery LLC

Inventor： Linghong Xie ,  Philip Glyn Jones ,  Kerry L. Spear ,  Noel Aaron Powell ,  Taleen G. Hanania ,  Vadim Alexandrov

IPC: C07D405/04 ,  C07D413/04 ,  C07D493/04 ,  C07D405/14 ,  C07D413/14

Abstract: Disclosed are compounds of Formula (I): and pharmaceutically acceptable salts thereof, wherein A, Ra, R1, R2, R3, R4, R6, w and n1 are defined and described herein; compositions thereof; and methods of use thereof. These compounds are useful for treating a variety of neurological and psychiatric disorders, such as those described herein.

公开(公告)号：US20190125722A1

公开(公告)日：2019-05-02

申请号：US16117450

申请日：2018-08-30

Applicant: Sunovion Pharmaceuticals Inc. ,  PGI Drug Discovery LLC

Inventor： Liming SHAO ,  John Emmerson CAMPBELL ,  Michael Charles HEWITT ,  Una CAMPBELL ,  Taleen G. HANANIA

IPC: A61K31/381 ,  C07D495/20 ,  C07D495/04 ,  C07D333/78 ,  C07D333/76 ,  A61K31/435 ,  C07D277/60 ,  A61K45/06 ,  A61K31/55 ,  C07D333/54

Abstract: Provided herein are multicyclic compounds, methods of their synthesis, pharmaceutical compositions comprising the compounds, and methods of their use. The compounds provided herein are useful for the treatment, prevention, and/or management of various neurological disorders, including but not limited to, psychosis and schizophrenia.

公开(公告)号：US20190031685A1

公开(公告)日：2019-01-31

申请号：US15947343

申请日：2018-04-06

Applicant: SUNOVION PHARMACEUTICALS INC.

Inventor： Philip G. Jones ,  Robert Lew ,  Kerry L. Spear ,  Linghong Xie

IPC: C07D513/04 ,  A61K31/4985 ,  C07D401/04 ,  A61K31/437 ,  C07D401/12 ,  A61K31/444 ,  A61K31/4375 ,  C07D495/04 ,  A61K31/519 ,  A61K31/4709 ,  C07D231/56 ,  A61K31/496 ,  C07D215/26 ,  C07D471/04 ,  A61K45/06 ,  A61K31/551 ,  C07D401/14 ,  C07D519/00

Abstract: Provided herein are heteroaryl compounds, methods of their synthesis, pharmaceutical compositions comprising the compounds, and methods of their use. In one embodiment, the compounds provided herein are useful for the treatment, prevention, and/or management of various disorders, such as CNS disorders and neurological disorders, including, but not limited to, e.g., psychosis, schizophrenia, depression, movement disorders, and Parkinson's disease.

公开(公告)号：US20180230120A1

公开(公告)日：2018-08-16

申请号：US15836261

申请日：2017-12-08

Applicant: Liming SHAO ,  Fengjiang WANG ,  Scott Christopher MALCOLM ,  Michael Charles HEWITT ,  Larry R. BUSH ,  Jianguo MA ,  Mark A. VARNEY ,  Una CAMPBELL ,  Sharon Rae ENGEL ,  Larry Wendell HARDY ,  Patrick KOCH ,  John E. CAMPELL

Inventor： Liming SHAO ,  Fengjiang WANG ,  Scott Christopher MALCOLM ,  Michael Charles HEWITT ,  Larry R. BUSH ,  Jianguo MA ,  Mark A. VARNEY ,  Una CAMPBELL ,  Sharon Rae ENGEL ,  Larry Wendell HARDY ,  Patrick KOCH ,  John E. CAMPELL

IPC: C07D333/20 ,  C07C211/17 ,  C07C211/29 ,  C07C215/42 ,  C07C215/44 ,  C07C217/52 ,  C07C217/74 ,  C07C323/32 ,  C07D207/06 ,  C07D207/08 ,  C07D211/14 ,  C07D265/14 ,  C07D277/28 ,  C07D295/06 ,  C07D307/52 ,  C07D317/58 ,  C07D317/72 ,  C07D319/06 ,  C07D491/056 ,  C07D211/16 ,  C07C211/40

CPC classification number: C07D333/20 ,  C07C211/17 ,  C07C211/29 ,  C07C211/40 ,  C07C215/42 ,  C07C215/44 ,  C07C217/52 ,  C07C217/74 ,  C07C323/32 ,  C07C2601/02 ,  C07C2601/08 ,  C07C2601/10 ,  C07C2601/14 ,  C07C2601/16 ,  C07C2602/08 ,  C07D207/06 ,  C07D207/08 ,  C07D211/14 ,  C07D211/16 ,  C07D265/14 ,  C07D277/28 ,  C07D295/06 ,  C07D307/52 ,  C07D317/58 ,  C07D317/72 ,  C07D319/06 ,  C07D491/056

Abstract: The invention relates to novel cyclohexylamine derivatives and their use in the treatment and/or prevention of central nervous system (CNS) disorders, such as depression, anxiety, schizophrenia and sleep disorder as well as methods for their synthesis. The invention also relates to pharmaceutical compositions containing the compounds of the invention, as well as methods of inhibiting reuptake of endogenous monoamines, such as dopamine, serotonin and norepinephrine from the synaptic cleft and methods of modulating one or more monoamine transporter.

公开(公告)号：US09951088B2

公开(公告)日：2018-04-24

申请号：US14399334

申请日：2013-05-09

Applicant: SUNOVION PHARMACEUTICALS INC.

Inventor： Philip G. Jones ,  Robert Lew ,  Kerry L. Spear ,  Linghong Xie

IPC: A61K31/506 ,  C07D513/04 ,  C07D471/04 ,  C07D401/14 ,  C07D215/26 ,  C07D231/56 ,  C07D401/04 ,  C07D401/12 ,  C07D495/04 ,  C07D519/00 ,  A61K31/437 ,  A61K31/4375 ,  A61K31/4709 ,  A61K31/496 ,  A61K31/4985 ,  A61K31/519 ,  A61K31/551 ,  A61K45/06 ,  A61K31/444

CPC classification number: C07D513/04 ,  A61K31/437 ,  A61K31/4375 ,  A61K31/444 ,  A61K31/4709 ,  A61K31/496 ,  A61K31/4985 ,  A61K31/519 ,  A61K31/551 ,  A61K45/06 ,  C07D215/26 ,  C07D231/56 ,  C07D401/04 ,  C07D401/12 ,  C07D401/14 ,  C07D471/04 ,  C07D495/04 ,  C07D519/00

Abstract: Provided herein are heteroaryl compounds, methods of their synthesis, pharmaceutical compositions comprising the compounds, and methods of their use. In one embodiment, the compounds provided herein are useful for the treatment, prevention, and/or management of various disorders, such as CNS disorders and neurological disorders, including, but not limited to, e.g., psychosis, schizophrenia, depression, movement disorders, and Parkinson's disease.

公开(公告)号：US20180072759A1

公开(公告)日：2018-03-15

申请号：US15818044

申请日：2017-11-20

Applicant: SUNOVION PHARMACEUTICALS INC.

Inventor： John Emmerson Campbell ,  Philip Wendell Jones ,  Michael Charles Hewitt

IPC: C07D519/00 ,  A61K31/5383 ,  A61K31/519 ,  A61K31/4985 ,  A61K31/4745 ,  A61K45/06 ,  C07D487/04 ,  C07D471/04 ,  A61K31/4375

CPC classification number: C07D519/00 ,  A61K31/4375 ,  A61K31/4745 ,  A61K31/4985 ,  A61K31/519 ,  A61K31/5383 ,  A61K45/06 ,  C07D471/04 ,  C07D487/04

Abstract: Provided herein are heteroaryl compounds, methods of their synthesis, pharmaceutical compositions comprising the compounds, and methods of their use. In one embodiment, the compounds provided herein are useful for the treatment, prevention, and/or management of various disorders, such as CNS disorders and metabolic disorders, including, but not limited to, e.g., neurological disorders, psychosis, schizophrenia, obesity, and diabetes.

公开(公告)号：US09884844B2

公开(公告)日：2018-02-06

申请号：US14758681

申请日：2013-12-31

Applicant: Sunovion Pharmaceuticals Inc.

Inventor： Qun Kevin Fang ,  Una Campbell ,  Kerry L. Spear

IPC: C07D401/04 ,  C07D491/113 ,  G01N33/50 ,  C07D401/14 ,  C07D413/14 ,  C07D487/10 ,  C07D498/10

CPC classification number: C07D401/04 ,  C07D401/14 ,  C07D413/14 ,  C07D487/10 ,  C07D491/113 ,  C07D498/10 ,  G01N33/5038

Abstract: Provided herein are heterocyclyl compounds, methods of their synthesis, pharmaceutical compositions comprising the compounds, and methods of their use. The compounds provided herein are useful for the treatment, prevention, and/or management of various neurological disorders, including but not limited to, psychosis and schizophrenia.

公开(公告)号：US09850204B2

公开(公告)日：2017-12-26

申请号：US14850338

申请日：2015-09-10

Applicant: Sunovion Pharmaceuticals Inc.

Inventor： Liming Shao ,  Fengjiang Wang ,  Scott C. Malcolm ,  Michael C. Hewitt

IPC: A61K31/4035 ,  C07D209/08 ,  C07D209/52 ,  C07D209/44

CPC classification number: C07D209/44 ,  A61K31/4035 ,  C07D209/08 ,  C07D209/52

Abstract: Provided herein are bicyclic compounds and methods of synthesis thereof. The compounds provided herein are useful for the treatment, prevention, and/or management of various neurological disorders. Compounds provided herein inhibit reuptake of endogenous monoamines, such as dopamine, serotonin and norepinephrine (e.g., from the synaptic cleft) and modulate one or more monoamine transporter. Pharmaceutical formulations containing the compounds are also provided.

公开(公告)号：US20170266133A1

公开(公告)日：2017-09-21

申请号：US15310344

申请日：2015-05-12

Applicant: SUNOVION PHARMACEUTICALS INC.

Inventor： Antony D. LOEBEL ,  Kenneth S. KOBLAN

IPC: A61K31/135 ,  A61K9/00

CPC classification number: A61K31/135 ,  A61K9/0053 ,  A61K9/4858 ,  A61K31/136

Abstract: Dosage forms and treatment regimens employing dasotraline for treating Attention Deficit Hyperactivity Disorder (ADHD) are disclosed. The compositions described herein exhibit no abuse potential.